Compare Banco Santander SA (SAN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Banco Santander SA vs Spyre Therapeutics Inc. Common Stock — how do they compare? Banco Santander SA trades at $13.39 (market cap $196.48B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Banco Santander SA is far larger — about 26.1× Spyre Therapeutics Inc. Common Stock's market cap, and Banco Santander SA pays a 2.14% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Banco Santander SA for 55 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SAN | SYRE | |
|---|---|---|
Market Cap | $196.48B | $7.52B |
Volume | 9,811,951 | 1,441,031 |
Sector | Financials | Health |
52-Week High | $15.05 | $108.92 |
52-Week Low | $9.65 | $22.18 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $362.68B | $6.52B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Banco Santander (SAN) trades at $13.41, down 0.52% on the day, with a bearish technical signal from moving averages and a mixed earnings history including a Q1 2026 beat. The company maintains strong profitability with a 26.25% net income margin and a 16.07% ROE, supported by record profits highlighted in recent earnings calls. Recent developments include the completion of the Webster acquisition, expanding its U.S. presence, and a dividend payment scheduled for November 2026.
The outlook is cautiously optimistic with analyst consensus at 'Moderate Buy' (64% buy ratings), but risks include declining cash flows from operations and rising debt-to-asset ratios. Revenue growth is projected to reach $61.9B in 2026, though net cash flow turned negative in 2024-2025, signaling potential liquidity pressures. Investors should weigh strong profitability against financial leverage and integration risks from acquisitions.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
